Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial.
Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial.
复制标题
DOI：
10.1038/s41372-022-01487-2
复制
发表时间：
2023-03
影响因子：
2.9
通讯作者：
Kraft, Walter K.
中科院分区：
文献类型：
--
作者：
Peltz, Gary;Jansson, Lauren M.;Adeniyi-Jones, Susan;Cohane, Carol;Drover, David;Shafer, Steven;Wang, Meiyue;Wu, Manhong;Govindaswami, Balaji;Jegatheesan, Priya;Argani, Cynthia;Khan, Salwa;Kraft, Walter K.
To determine if treatment with a 5-HT3 antagonist (ondansetron) reduces need for opioid therapy in infants at risk for neonatal opioid withdrawal syndrome (NOWS). A multicenter, randomized, placebo controlled, double blind clinical trial of ninety (90) infants. The intervention arms were intravenous ondansetron or placebo during labor followed by a daily dose of ondansetron or placebo in infants for five days. Twenty-two (49%) ondansetron-treated and 26 (63%) placebo-treated infants required pharmacologic treatment (p>0.05). The Finnegan score was lower in the ondansetron-treated group (4.6 vs. 5.6, p=0.02). A non-significant trend was noted for the duration of hospitalization. There was no difference in need for phenobarbital or clonidine therapy, or total dose of morphine in the first 15 days of NOWS treatment. Ondansetron treatment reduced the severity of NOWS symptoms; and there was an indication that it could reduce the length of stay.
登录
查看更多内容
影响因子：
3.4
作者：
SIMPSON, KH;MURPHY, P;WHELAN, P
通讯作者：
WHELAN, P
DOI：
10.1038/s41372-018-0088-9
发表时间：
2018-05
期刊：
Journal of perinatology : official journal of the California Perinatal Association
影响因子：
--
作者：
Merhar SL;McAllister JM;Wedig-Stevie KE;Klein AC;Meinzen-Derr J;Poindexter BB
通讯作者：
Poindexter BB
影响因子：
3.5
作者：
Ornoy, A
通讯作者：
Ornoy, A
影响因子：
4.7
作者：
Portenoy, Russell K.;Thomas, Jay;Israel, Robert J.
通讯作者：
Israel, Robert J.
影响因子：
8
作者：
Patrick, Stephen W.;Barfield, Wanda D.;Poindexter, Brenda B.
通讯作者：
Poindexter, Brenda B.